InVivoMAb anti-mouse CD8α（clone 2.43）:Bioxcell簡(jiǎn)介

產(chǎn)品規(guī)格

1/5/25/50/100mg

抗體亞型

Rat IgG2b, κ

推薦同型對(duì)照

InVivoMAb rat IgG2b isotype control, anti-keyhole limpet hemocyanin（貨號(hào)：BE0090）

推薦抗體稀釋液

InVivoPure™ pH 7.0 Dilution Buffer（貨號(hào)：IP0070）

免疫原

Mouse CTL clone L3

應(yīng)用

in vivo CD8+ T cell depletion

Western blot

產(chǎn)品形式

PBS, pH 7.0

Contains no stabilizers or preservatives

內(nèi)毒素水平

<2EU/mg (<0.002EU/μg)

使用 LAL gel clotting 測(cè)定

純度

>95% Determined by SDS-PAGE

無(wú)菌處理

0.2 μM filtered

生產(chǎn)形式

從組織培養(yǎng)上清液中純化得到。

純化形式

Protein G

RRID

AB_1125541

分子量大小

150 kDa

保存條件

抗體原溶液應(yīng)保存在4°C條件下，不要冷凍保存。

in vivo CD8+ T cell depletion

Li, J., et al. (2018). “Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8(+) T Cells.” Immunity 48(4): 773-786 e775.

in vivo CD8+ T cell depletion

Moynihan, K. D., et al. (2016). “Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.” Nat Med. doi: 10.1038/nm.4200.